Cronos Group Partners with Geocann to Leverage VESIsorb® Delivery Technology for Faster Absorption
June 27 2022 - 7:30AM
Cronos Group Inc. (NASDAQ: CRON) (TSX: CRON) (“Cronos” or the
“Company”) is pleased to announce the launch of the first
of what is expected to be a range of products, in partnership with
Geocann, which will utilize the advanced VESIsorb® delivery system.
This technology provides better bioavailability and faster
absorption. VESIsorb® formulations have set the industry benchmark
in peer-reviewed published studies, delivering superior
pharmacokinetic performance, including fast absorption, higher
plasma concentration, and greater area under the curve.
“We are committed to bringing breakthrough innovations to the
market, providing consumers with differentiated and high-quality
products,” said Mike Gorenstein, Chairman, President and Chief
Executive Officer, Cronos. “Working with Geocann’s technology
enables us to expand our product offering to bring consumers a
fast-acting cannabinoid product with a quicker onset than
previously available, along with improved efficacy, helping enhance
and differentiate effect and experience.”
VESIsorb® is the leading delivery system innovation for
dramatically improving the bioavailability of difficult-to-absorb
ingredients, like cannabinoids and terpenes. This patented
technology has been shown to have faster absorption in both
well-designed pilot and peer-reviewed published studies. Geocann is
the exclusive supplier of the VESIsorb® delivery system for
cannabinoids, terpenes, and flavonoid formulations, and is
well-recognized for its substantial investments in research and
product development in order to meet the needs of the
marketplace.
“As leading companies in our respective sectors, Geocann and
Cronos are uniquely positioned to set new industry benchmarks for
the performance of cannabinoid products,” Jesse Lopez, Chief
Executive Officer and founder of Geocann, said. “Most importantly,
Geocann is proud to support the innovative brands under the Cronos
umbrella.”
The first VESIsorb® formulated product the companies have
launched together are the CBD Gel Capsules by Lord Jones®. The
companies look forward to collaborating in the future on innovative
products and formulations.
About Cronos Cronos is an innovative global
cannabinoid company committed to building disruptive intellectual
property by advancing cannabis research, technology and product
development. With a passion to responsibly elevate the consumer
experience, Cronos is building an iconic brand portfolio. Cronos’
diverse international brand portfolio includes Spinach®, PEACE
NATURALS®, Lord Jones®, Happy Dance® and PEACE+™. For more
information about Cronos and its brands, please visit:
thecronosgroup.com.
Cronos Group ContactShayne LaidlawInvestor
RelationsTel: (416)
504-0004investor.relations@thecronosgroup.com
About GeocannGeocann is a global cannabis
organization that combines clinically-researched cannabinoids and
terpenes with technologically-advanced drug delivery system
technologies that increase absorption and bioavailability for
maximum health benefits. These product formulations offer novel
solutions that address unmet marketplace needs and provide
unmatched competitive advantages that are backed by a robust body
of clinical studies and proprietary scientific evidence. Geocann
owns a robust intellectual property portfolio, including the
worldwide exclusivity for cannabinoids, terpenes, and flavonoids
formulated with the VESIsorb® drug delivery system technology
platform. For more information, please visit www.geocann.com.
For more information and interview requests, please contact Sam
Davidson at + 1 970-657-2479 or sam@geocann.com.
Forward-looking Statements of Cronos Group
Inc.This press release may contain information that may
constitute “forward-looking information” or “forward-looking
statements” within the meaning of applicable Canadian and U.S.
securities laws (collectively, “Forward-looking Statements”). All
information contained herein that is not clearly historical in
nature may constitute Forward-looking Statements. In some cases,
Forward-looking Statements can be identified by the use of
forward-looking terminology such as “may”, “will”, “expect”,
“plan”, “anticipate”, “intend”, “potential”, “estimate”, “believe”
or the negative of these terms, or other similar expressions
intended to identify Forward-looking Statements. Some of the
Forward-looking Statements contained in this press release include
the companies’ launch of a range of products and future
collaboration on innovative products and formulations and Cronos’
intention to build an international iconic brand portfolio and
develop disruptive intellectual property. Forward-looking
Statements are necessarily based upon a number of estimates and
assumptions that, while considered reasonable by management, are
inherently subject to significant business, economic and
competitive risks, financial results, results, performance or
achievements expressed or implied by those Forward-looking
Statements and the Forward-looking Statements are not guarantees of
future performance. A discussion of some of the material risks
applicable to the Company can be found in the Company’s Annual
Report on Form 10-K for the year ended December 31, 2021 and
Quarterly Report on Form 10-Q for the period ended March 31, 2022,
both have which been filed on SEDAR and EDGAR and can be accessed
at www.sedar.com and www.sec.gov/edgar, respectively. Any
Forward-looking Statement included in this press release is made as
of the date of this press release and, except as required by law,
Cronos Group disclaims any obligation to update or revise any
Forward-looking Statement. Readers are cautioned not to put undue
reliance on any Forward-looking Statement.
Cronos (NASDAQ:CRON)
Historical Stock Chart
From Apr 2024 to May 2024
Cronos (NASDAQ:CRON)
Historical Stock Chart
From May 2023 to May 2024